Biotest – facts and figures

Financial figures

Financial Figures
   20103)  2011  2012  2013  2014  2015 
  in EUR millions1)                  
  Sales 412,5   422,0   440,0   500,8   582,0   589,6  
  EBITDA 69,8   72,4   76,2   85,6   85,9   22,4  
  EBIT 42,9   41,6   44,7   53,8   53,4   -71,8  
  Profit before tax 28,4   28,6   36,5   47,8   46,9   -74,3  
  Net profit 19,6   18,7   23,1   32,0   19,2   -82,5  
  Balance Sheet Total 632,3   682,8   682,3   886,5   1.032,6   962,7  
  Shareholders’ equity 307,6   346,7   369,4   460,7   480,2   412,3  
  Dividend in EUR4)                  
  Ordinary 0,13   0,15   0,17   0,19   0,20   0,02  
  Preference 0,15   0,17   0,19   0,21   0,22   0,04  
  Staff 1.611   1.662   1.727   1.997   2.158   2.271  

   2014 2015 2016
  in EUR millions1) Q1   Q2   Q3   Q4   Q1   Q2   Q3   Q4   Q1   Q2   Q3  
  Sales 122,2   141,9   145,8   172,1   142,5   145,2   130,2   171,7   147,1   159,0   149,5  
  EBIT 10,7   15,8   8,8   18,1   0,1   2,2   -84,3   10,2   8,6   9,6   7,9  
  Profit before tax 7,8   13,9   10,6   14,6   4,2   -2,1   -87,3   10,9   4,7   9,2   2,2  
  Profit after tax 5,0   8,8   5,5   -0,1   1,4   -3,6   -85,8   5,5   1,8   5,9   -9,4  
  Balance Sheet Total 902,5   914,3   932,1   1032,6   1.072,2   1052,2   962,8   962,7   968,3   981,9   962,4  
  Shareholders’ equity 465,7   468,1   486,8   480,2   502,9   484,0   398,2   412,3   410,1   416,7   407,0  
  Staff 2.090   2.130   2.137   2.158   2.188   2.218   2.215   2.271   2.324   2.340   2.474  
1) all figures according to IFRS
2) Continuing Operations after disposal of the transfusion and transplantation activities to Bio-Rad Laboratories, Inc.
3) Continuing Operations after disposal of the transfusion and transplantation activities to Bio-Rad Laboratories, Inc. and the microbiological Monitoring to Merck KGaA
4)On 15 July 2015 Biotest AG reorganises stock exchange listing due to share split with the ration one to three. By implementing the capital increase and the share split the existing shareholder structure does not change. The share capital of Biotest AG amounted to € 33,767,639.04 before the capital increase and was divided into 6,595,242 ordinary shares and 6,595,242 preference shares without voting rights. Thus, one ordinary or preference share had a proportional amount of the share capital of € 2.56. After the implementation of the capital increase from capital funds by € 5,803,812.96 to € 39,571,452.00 without issuing new shares and the share split, each former holder of one existing ordinary or preference share now holds three ordinary or preference shares with a proportional amount of the share capital of € 1.00. After capital increase and share split the amount of ordinary shares and prefernece share amounts to each 19,785,726 shares. The previous year's figures have been adjusted to the new amount of shares.